10 May 2017 - The EMA\'s 2016 annual report published today focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life.

In 2016, the Agency recommended a marketing authorisation for 81 medicines for human use, including 27 new active substances. Many of these innovative substances build on the advances made in biomedical science and have the potential to make a difference for patients.

Read EMA press release